Published on October 7, 2009 at 5:55 AM
Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced completion of a research report concerning its fluorescent stem cells, http://www.vitrobiopharma.com/wp-content/uploads/2009/10/fluorescent-msc-10-3.pdf. This report revealed transfer of fluorescent to differentiated cells including chondrocytes, cells responsible for making cartilage. Fluorescent stem cells allow tracking of stem cells following transplantation and studies of stem cell homing or migration to cancer stem cells, sites of cellular injury or inflammation. This work may lead to new developments for targeting drug delivery and stem cell therapy. Vitro Biopharma’s new research shows that its fluorescent stem cells also have application to studies of stem cell differentiation and thus to expanded investigations of the therapeutic uses of stem cells.
Vitro Biopharma supplies three different kinds of fluorescent stem cell lines labeled by different methods and fluorescent probes, including both green and red fluorescent stem cells. Another stem cell type offered by Vitro Biopharma is labeled with green fluorescent protein, a commonly used marker in biological research. The new research shows that not only do stem cells retain fluorescence, but the fluorescent label is also transferred to differentiated cells including chondrocytes. Red fluorescent-labeled stem cells showed enhanced fluorescence of differentiated cells indicating further applications of this stem cell line for use in the advancement of stem cell technology.
Dr. Jim Musick, Vitro’s CEO said, “We are pleased to report our research showing application of our fluorescent stem cells to not only to stem cell localization, but also to stem cell differentiation. This new development allows expanded uses of our fluorescent stem cells, which to our knowledge are not available from other vendors. We hope that our products for stem cell research and drug development will contribute to the advancement of stem cell therapy to conditions without prior treatment options including not only degenerative diseases but also aggressive forms of poor prognosis cancer.”
http://www.vitrobiopharma.com